

# A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

Last Update: Jul 29, 2025

A Multicenter Study of Secukinumab, With a Randomized Double-blind, Placebo-controlled Withdrawal-retreatment Period, to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

ClinicalTrials.gov Identifier:

[NCT05622708](#)

Novartis Reference Number:CAIN457I2401

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

## Study Description

This study will establish whether prolonged chronic dosing with secukinumab is needed in participants with Non-radiographic axial spondyloarthritis, (nr-axSpA) who have achieved remission. Remission is defined as Ankylosing Spondylitis Disease Activity Score - C-reactive protein (ASDAS-CRP) Inactive Disease (ID) response (ASDAS-CRP  $\leq$  1.3). Maintenance of remission on continued secukinumab treatment will be evaluated compared to placebo using a randomized withdrawal design. The primary outcome measure for this study is the proportion of participants remaining flare-free at Week 120. This study will establish whether prolonged chronic dosing with secukinumab is needed in participants with nr-axSpA who have achieved remission. Remission is defined as Ankylosing Spondylitis Disease Activity Score - C-reactive protein (ASDAS-CRP) Inactive Disease (ID) response Inactive Disease (ID) response (ASDAS-CRP  $\leq$  1.3). The maintenance of remission on continued secukinumab treatment will be evaluated compared to placebo using a randomized withdrawal design. The primary outcome measure for this study is the proportion of participants remaining flare-free at Week 120.

Study treatment will be as follows:

- \* Open-label Secukinumab PFS (prefilled syringe) will be labeled as AIN457 150mg/1mL
- \* Double-blind Secukinumab and Placebo PFS will be labeled as AIN457 150mg/1mL/Placebo.

Study duration will be up to 128 weeks from Baseline.

The treatment duration will be up to 120 weeks with last treatment administration at Week 116.

In the Treatment Period 1 participant will attend a site visit approximately 1 month after Baseline and approximately every 12 weeks thereafter. In the Treatment Period 2 participant will attend site visits approximately every 4 weeks.

Non-radiographic Axial Spondyloarthritis

Phase

Phase4

Overall Status

Recruiting

Number of Participants

340

Start Date

Mar 28, 2023

Completion Date

Jun 21, 2030

Gender

All

Age(s)

18 Years - 100 Years (Adult, Older Adult)

## Interventions

Drug

### Placebo

Treatment Period 2: Double-blind placebo PFS s.c. every 4 weeks from Week 56 to Week 116.

Drug

### Secukinumab

Treatment Period 2: Double-blind secukinumab 150 mg PFS s.c. every 4 weeks from Week 56 to Week 116.

Escape re-treatment (during Treatment Period 2): Open-label secukinumab 150 mg PFS s.c.

## Eligibility Criteria

Inclusion Criteria:

\* Male or non-pregnant, non-lactating female participants at least 18 years of age

\* Clinical diagnosis of axSpA AND according to ASAS axSpA criteria:

1. Inflammatory back pain for at least 6 months

2. Onset before 45 years of age

3. Sacroiliitis on MRI (magnetic resonance imaging) (as assessed by central reader) with  $\geq 1$  SpA feature OR HLA-B-27 positive with  $\geq 2$  SpA features

\* Objective signs of inflammation at screening, evident by either MRI with Sacroiliac Joint inflammation (as assessed by central reader) AND / OR hsCRP  $>$  ULN (as defined by the central lab)

\* Active axSpA as assessed by total BASDAI  $\geq 4$  cm (0-10 cm) at baseline.

\* Spinal pain as measured by BASDAI question #2  $\geq 4$  cm (0-10 cm) at baseline.

\* Total back pain as measured by VAS (visual analog scale)  $\geq 40$  mm (0-100 mm) at baseline.

\* Participants should have been on at least 2 different NSAIDs (non-steroidal anti-inflammatory drugs) at the highest recommended dose for at least 4 weeks in total prior to baseline with an inadequate response or failure to respond, or less if therapy had to be withdrawn due to intolerance, toxicity or contraindications.

## Exclusion Criteria:

- \* Participants with radiographic evidence for sacroiliitis, grade  $\geq 2$  bilaterally or grade  $\geq 3$  unilaterally (radiological criterion according to the modified New York diagnostic criteria for AS) as assessed by central reader.
- \* Participants taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine).
- \* Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or IL-17 receptor or previous treatment with immunomodulatory biologic agents including those targeting TNF $\alpha$  (tumor necrosis factor  $\alpha$ ) (unless participants discontinued the treatment with TNF $\alpha$  inhibitor due to a reason other than efficacy \[primary or secondary lack of efficacy, inadequate response\] and only after appropriate wash-out period prior to baseline was observed).
- \* History of hypersensitivity to the study drug or its excipients or to drugs of similar chemical classes.
- \* Active ongoing inflammatory diseases other than nr-axSpA that might confound the evaluation of the benefit of secukinumab therapy, including uveitis.
- \* Active inflammatory bowel disease.
- \* History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection.

## Belgium

### Novartis Investigative Site

Recruiting

Bruges,8000,Belgium

### Novartis Investigative Site

Recruiting

Genk,3600,Belgium

### Novartis Investigative Site

Recruiting

Ghent,9000,Belgium

### Novartis Investigative Site

Recruiting

Mons,7000,Belgium

## Brazil

### Novartis Investigative Site

Recruiting

Barretos,São Paulo,14784 400,Brazil

### Novartis Investigative Site

Recruiting

Juiz de Fora, MG, 36010-570, Brazil

**Novartis Investigative Site**

Recruiting

Porto Alegre, RS, 90480-000, Brazil

**Colombia**

**Novartis Investigative Site**

Recruiting

Barranquilla, Atlántico, 080020, Colombia

**Novartis Investigative Site**

Recruiting

Bogota, Cundinamarca, 110111, Colombia

**Novartis Investigative Site**

Recruiting

Chia, Cundinamarca, 250001, Colombia

**Novartis Investigative Site**

Recruiting

Bucaramanga, Santander Department, 0001, Colombia

**Novartis Investigative Site**

Recruiting

Bogotá, 110221, Colombia

**Czechia**

**Novartis Investigative Site**

Recruiting

Uherské Hradiště, 686 01, Czechia

**Novartis Investigative Site**

Recruiting

Praha,150 06,Czechia

**Novartis Investigative Site**

Recruiting

Prague,14900,Czechia

**Novartis Investigative Site**

Recruiting

Praha 2,128 50,Czechia

**France**

**Novartis Investigative Site**

Recruiting

Chambray-lès-Tours,37170,France

**Novartis Investigative Site**

Recruiting

Toulouse,31059,France

**Novartis Investigative Site**

Recruiting

Paris,75012,France

**Novartis Investigative Site**

Recruiting

Le Mans,72000,France

**Novartis Investigative Site**

Recruiting

Nice,06001,France

**Novartis Investigative Site**

Recruiting

Orleans,45100,France

**Germany**

**Novartis Investigative Site**

**Novartis Investigative Site**

Recruiting

Hamburg,22415,Germany

**Novartis Investigative Site**

Recruiting

Herne,44649,Germany

**Novartis Investigative Site**

Recruiting

Ludwigshafen,67063,Germany

**Novartis Investigative Site**

Recruiting

Magdeburg,39110,Germany

**Novartis Investigative Site**

Recruiting

Bad Doberan,18209,Germany

**Novartis Investigative Site**

Recruiting

Ratingen,40878,Germany

**Novartis Investigative Site**

Recruiting

Berlin,12161,Germany

**Novartis Investigative Site**

Recruiting

Freiburg,79106,Germany

**Novartis Investigative Site**

Recruiting

Berlin,13353,Germany

**Novartis Investigative Site**

Recruiting

Rendsburg,24768,Germany

**Novartis Investigative Site**

Recruiting

Berlin,13125,Germany

**Hungary**

**Novartis Investigative Site**

Recruiting

Veszprem,8200,Hungary

**Novartis Investigative Site**

Recruiting

Miskolc,3526,Hungary

**Novartis Investigative Site**

Recruiting

Budapest,1023,Hungary

**Novartis Investigative Site**

Recruiting

Debrecen,4032,Hungary

**Novartis Investigative Site**

Recruiting

Eger,3300,Hungary

**Novartis Investigative Site**

Recruiting

Kistarcsa,2143,Hungary

**Novartis Investigative Site**

Recruiting

Szeged,6720,Hungary

**Novartis Investigative Site**

Recruiting

Szekesfehervar,Fejer,8000,Hungary

**Israel**

**Novartis Investigative Site**

Recruiting

Tel Aviv,6423906,Israel

**Novartis Investigative Site**

Recruiting

Haifa,3104802,Israel

**Novartis Investigative Site**

Recruiting

Kfar Saba,4428164,Israel

**Novartis Investigative Site**

Recruiting

Ramat Gan,5265601,Israel

**Italy**

**Novartis Investigative Site**

Recruiting

Verona,VR,3712,Italy

**Novartis Investigative Site**

Recruiting

Roma,RM,00161,Italy

**Novartis Investigative Site**

Recruiting

Firenze,FI,50134,Italy



### **Novartis Investigative Site**

Recruiting

Torino,TO,10128,Italy

### **Novartis Investigative Site**

Recruiting

Milano,MI,20100,Italy

### **Novartis Investigative Site**

Recruiting

Negrar,VR,37024,Italy

### **Novartis Investigative Site**

Recruiting

Bologna,BO,40136,Italy

### **Novartis Investigative Site**

Recruiting

Ancona,AN,60126,Italy

### **Malaysia**

### **Novartis Investigative Site**

Recruiting

Kuching,Sarawak,93586,Malaysia

### **Novartis Investigative Site**

Recruiting

Kuala Lumpur,59100,Malaysia

### **Novartis Investigative Site**

Recruiting

Selangor Darul Ehsan,68100,Malaysia

### **Mexico**

### **Novartis Investigative Site**

Recruiting

Guadalajara,Jalisco,44650,Mexico

**Novartis Investigative Site**

Recruiting

Guadalajara,Jalisco,44690,Mexico

**Novartis Investigative Site**

Recruiting

Mérida,Yucatán,97070,Mexico

**Novartis Investigative Site**

Recruiting

Chihuahua City,31000,Mexico

**Netherlands**

**Novartis Investigative Site**

Recruiting

Maastricht,6229 hx,Netherlands

**Novartis Investigative Site**

Recruiting

Amsterdam,1105 az,Netherlands

**Novartis Investigative Site**

Recruiting

Heerlen,6419 pc,Netherlands

**Philippines**

**Novartis Investigative Site**

Recruiting

Makati City,National Capital Region,1218,Philippines

**Novartis Investigative Site**

Recruiting

Manila,1008,Philippines

## **Poland**

### **Novartis Investigative Site**

Recruiting

Sochaczew,96-500,Poland

### **Novartis Investigative Site**

Recruiting

Warszawa,02 637,Poland

### **Novartis Investigative Site**

Recruiting

Torun,87-100,Poland

### **Novartis Investigative Site**

Recruiting

Krakow,Lesser Poland Voivodeship,30-727,Poland

### **Novartis Investigative Site**

Recruiting

Bialystok,15-351,Poland

### **Novartis Investigative Site**

Recruiting

Bydgoszcz,85 168,Poland

### **Novartis Investigative Site**

Recruiting

Krakow,30 002,Poland

## **Romania**

### **Novartis Investigative Site**

Recruiting

Cluj-Napoca,400006,Romania

**Novartis Investigative Site**

Recruiting

Bucuresti,011172,Romania

**Novartis Investigative Site**

Recruiting

Sibiu,550245,Romania

**Novartis Investigative Site**

Recruiting

Suceava,727525,Romania

**Novartis Investigative Site**

Recruiting

Brasov,500283,Romania

**Novartis Investigative Site**

Recruiting

Bucharest,011055,Romania

**Thailand****Novartis Investigative Site**

Recruiting

Bangkok,10400,Thailand

**Novartis Investigative Site**

Recruiting

Bangkok,10700,Thailand

**Turkey****Novartis Investigative Site**

Recruiting

Konya,42080,Turkey

**Novartis Investigative Site**

Recruiting

Adana,01160,Turkey

### **Turkey (Türkiye)**

#### **Novartis Investigative Site**

Recruiting

Adana,01160,Turkey (Türkiye)

#### **Novartis Investigative Site**

Recruiting

Konya,42080,Turkey (Türkiye)

### **Vietnam**

#### **Novartis Investigative Site**

Recruiting

Ho Chi Minh City,VNM,700000,Vietnam

## **Worldwide Contacts**

If the location of your choosing does not feature any contact detail, please reach out using the information below.

### **Novartis Pharmaceuticals**

Phone: +41613241111

Email: [novartis.email@novartis.com](mailto:novartis.email@novartis.com)

---

**Source URL:** <https://prod1.novartis.com/clinicaltrials/study/nct05622708>

### **List of links present in page**

1. <https://clinicaltrials.gov/ct2/show/NCT05622708>
2. [#trial-eligibility](#)
3. tel:+41613241111
4. <mailto:novartis.email@novartis.com>